Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02932410 · ClinicalTrials.gov registry record · Phase 3

A Study to Assess Whether Macitentan Delays Disease Progression in Children With Pulmonary Arterial Hypertension (PAH)

A Phase 3 study, sponsored by Actelion.

Completed
Registry status
Phase 3
Development phase
165
Enrollment target

NCT02932410: Completed Phase 3 study, sponsored by Actelion.

NCT02932410 is a Phase 3 study that has completed, run by Actelion. The registered enrollment target is 165 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (79% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02932410, a Phase 3 study, has completed, sponsored by Actelion.

COMPLETED
Registry status
Phase 3
Development phase
165 participants
Enrollment target

Study Summary

This is a prospective, multicenter, open-label, randomized, controlled, parallel Phase 3 study with an open-label single-arm extension period to evaluate pharmacokinetics (PK), safety and efficacy of macitentan in children with pulmonary arterial hypertension (PAH).

Primary Outcome

Observed steady-state trough (pre-dose) plasma concentration of macitentan and aprocitentan (active metabolite) at Week 12 based on body weight were reported. This outcome measure was planned to be analyzed for specified arms only.

Interventions

  • DRUG Macitentan
  • OTHER Standard-of-care

Trial Details

FieldValue
Enrollment Target 165 participants
Start Date 2017-10-24
Est. Completion 2025-11-27
Phase Phase 3
Actelion

63 total trials

What the finished NCT02932410 record still lists

NCT02932410 is an interventional study that assigns participants to a tested intervention. The registered 165 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (79% lower).

The record links to 0 conditions, and to 2 interventions - of which Macitentan is the first listed.

NCT02932410 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02932410 about?

NCT02932410 is a clinical study titled "A Study to Assess Whether Macitentan Delays Disease Progression in Children With Pulmonary Arterial Hypertension (PAH)". This is a prospective, multicenter, open-label, randomized, controlled, parallel Phase 3 study with an open-label single-arm extension period to evaluate pharmacokinetics (PK), safety and efficacy of macitentan in children with pulmonary arterial hypertension (PAH).

What is the current status of trial NCT02932410?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 165 participants. The study started on 2017-10-24. Estimated completion is 2025-11-27.

What interventions are being tested in trial NCT02932410?

The interventions under investigation include: Macitentan (DRUG), Standard-of-care (OTHER).

Who is sponsoring clinical trial NCT02932410?

This trial is sponsored by Actelion, which has 63 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02932410's enrollment target sits among peer trials

165 1465th of 2000 higher than 531 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02387255 · 165 participants

    Magnetic Resonance Elastography in Patients With Abdominal Aortic Aneurysms

  • NCT03351348 · 165 participants · Phase 3

    Bupivacaine vs Placebo for Unilateral Mastectomy Surgical Site Post-operative Pain Control

  • NCT03830320 · 165 participants · Phase 1

    Positron Emission Tomography (PET) Imaging of Thrombosis

  • NCT04289571 · 165 participants · Phase 1

    Virtual Reality Mobility Assessment of Functional Vision in Retinal Disease

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02932410, the US trial registry maintained by the National Library of Medicine. NCT02932410 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.